ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2004
Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02754739 (Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.Psychological medicine · 2019Pooled it
- A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.Schizophrenia research · 2014Trial
- Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients.Atherosclerosis · 2009Trial
- High doses of rosuvastatin induce impaired branched-chain amino acid catabolism and lead to insulin resistance.Experimental physiology · 2023Article
- Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.Endocrinology, diabetes & metabolism · 2022Article
- Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications.Diabetology international · 2017Article
- Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion.EBioMedicine · 2016Article
- Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.Acta pharmacologica Sinica · 2014Article
- Cardiovascular disease-related parameters and oxidative stress in SHROB rats, a model for metabolic syndrome.PloS one · 2014Article
- Diabetogenic effect of statins: a double-edged sword?Diabetes & metabolism journal · 2013Article
- The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats.Journal of diabetes research · 2013Article
- Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.Journal of diabetes investigation · 2012Article
- Central versus peripheral cardiovascular risk in metabolic syndrome.Frontiers in physiology · 2012Article
- Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.Clinical pharmacology and therapeutics · 2011Article
- Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.Journal of lipid research · 2010Article
- Effect of simvastatin on burn-induced alterations in tissue specific glucose metabolism: implications for burn associated insulin resistance.International journal of molecular medicine · 2010Article
- Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.Cancer science · 2010Article
- Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: insulin resistance, friend or foe?Nutrition & metabolism · 2009Article
- Oxidized LDL and the metabolic syndrome.Future lipidology · 2008Article
- A novel membrane-based anti-diabetic action of atorvastatin.Biochemical and biophysical research communications · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn West of Scotland Coronary Prevention Study (WOSCOPS), development of type 2 diabetes mellitus (DM) was found to decrease by 30% in pravastatin-treated patients. In the study, it is suggested that pleiotropic effects of pravastatin may be responsible too as well as its lipid lowering effect.
objectiveThe aim of this study was to assess the effects of pravastatin treatment on the insulin resistance in patients with metabolic syndrome with impaired glucose tolerance (IGT), by Homeostasis Model Assessment (HOMA) test, insulin sensitivity indices and glucose half activation time (glucose t1/2).
methodsStudy population consisted of 25 women who were diagnosed with metabolic syndrome. At baseline and 10 weeks after the 20 mg/daily tablet pravastatin treatment, waist/hip circumference, body weight and arterial blood pressure measurements, plasma glucose, total cholesterol, triglyceride, high density lipoprotein (HDL)-cholesterol, transaminases, glycosylated haemoglobin (A1C) and insulin level measurements were obtained along with HOMA test and insulin tolerance test after 12 h of fasting. Insulin sensitivity indices and glucose t1/2 were assessed.
resultsAfter the treatment, a statistically significant decrease was observed in arterial blood pressure values (P < 0.0001). While plasma total cholesterol, low density lipoprotein (LDL)-cholesterol, and triglyceride levels were found to decrease significantly and HDL-cholesterol levels increased significantly, a decrease in baseline insulin levels, an increase in insulin sensitivity levels were observed along with an decrease in glucose t1/2. Related to the improvement in aforementioned parameters, statistically significant decreases were noted in HOMA, postprandial and fasting glucose levels and A1C values (P < 0.0001).
conclusionOur study suggests that using pravastatin in the dyslipidemia treatment of metabolic syndrome with IGT may be an effective approach by its advantageous effects on insulin resistance. Based on this result, it is possible to say that this can be a risk lowering treatment approach for the development of type 2 DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.